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Abstract
A 48-year-old man was admitted to our hospital with complaints of productive cough, anorexia, and sweating from two weeks ago.
Laboratory studies revealed an increased level of liver enzymes. The work-up of serological markers was negative for both infectious
and non-infectious causes of hepatitis. He denied smoking, alcohol consumption, occupational exposures, and illicit drug use. In-
terestingly, he had a history of contact with an antifungal toxin called tebuconazole about 15 days before admission. In toxicological
examinations using gas chromatography with a nitrogen-phosphorus detector, the cause of poisoning was revealed to be fungicide
tebuconazole. To confirm the causal relationship between toxin and hepatitis, exposure avoidance and repeated testing were con-
sidered. Complete recovery was achieved in all clinical symptoms and laboratory findings. We suggest that tebuconazole-induced
hepatitis should be considered in farmers exposed to this fungicide.
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1. Introduction
Tebuconazole is a triazole fungicide used agricultur-
ally for the treatment of plant pathogenic fungi. Its mech-
anism of action is to inhibit the biosynthesis of sterol in
fungi (1). It has been listed among the top 10 active in-
gredients in the EU’s fungicide report (2). Tebuconazole is
applied to various products, in particular, vegetables and
some fruits such as grapes (3).
So far, the pathways of tebuconazole biotransforma-
tion have not been studied in humans. In animal mod-
els, however, the biotransformation involves the sequen-
tial oxidation of a methyl group in the butyl chain to yield
alcohol and carboxylic acid metabolites Tebuconazole-OH
(tebuconazole-1-hydroxy) and Tebuconazole-COOH (tebu-
conazole carboxylic acid). In the next step, tebuconazole-
OH is conjugated to form the glucuronide and sulfate con-
jugates, which are excreted in the urine. Unchanged tebu-
conazole is excreted in small amounts via the urine, as well
(4). An overview of the tebuconazole metabolic pathway is
shown in Figure 1.
Here, we report the case of a 48-year-old male patient
with tebuconazole-induced hepatitis from Iran, who was
successfully treated merely with exposure avoidance.
2. Case Presentation
According to the requirements of the local ethics com-
mittee, written informed consent was obtained for the
publication of the patient’s medical information. In May
2018, a 48-year-old male with respiratory complaints in-
cluding productive cough, anorexia, weakness, weight loss
of 4 kg, sweating, and increased levels of liver enzymes
from two weeks ago was referred to the clinic of infectious
diseases at Imam Khomeini Hospital, Ardabil, Iran. The
patient was living in a rural area. The occupational his-
tory taking showed that the patient was a farmer currently
working on planting barley. He had a history of constant
contact with agricultural pesticides. No past history of
medical or surgical conditions was reported.
On the physical examination, the patient appeared to
be ill. On admission, blood pressure was 125/75 mmHg, the
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heart rate was 96 beats per minute, the respiratory rate was
22 per minute, and the body temperature was 37.4°C. Chest
auscultation revealed generalized expiratory wheezing in
both lung fields. There was tenderness to palpation in the
right upper quadrant of the abdomen. The liver and spleen
were not palpable.
Initial investigations showed increased levels of liver
enzymes. The baseline laboratory test results are shown
in Table 1. His chest X-ray revealed no abnormality and the
sputum smear stains were negative for Mycobacterium tu-
berculosis. Serological markers for the diagnosis of hepati-
tis B virus infection such as Anti-HBc (hepatitis B core anti-
body), HBsAg (hepatitis B surface antigen), HBeAg (hepati-
tis B envelope antigen), and Anti-HBe (antibody to HBeAg)
were non-reactive. Tests to detect anti-hepatitis E virus
(HEV) and anti-hepatitis A virus (HAV) were both negative
for immunoglobulin M (IgM). A test to detect hepatitis
C antibody (anti-HCV) was negative. Based on the find-
ings, acute and chronic viral hepatitis was ruled out. An-
tibodies for the detection of human immunodeficiency
viruses type-1 and type-2 (HIV-1 and HIV-2) were negative.
Tests to detect antibodies to Epstein-Barr virus (EBV) and
cytomegalovirus (CMV) were both negative for IgM. In
the next step, iron profile, serum ceruloplasmin, alpha-
1 antitrypsin, and autoimmune markers were also eval-
uated, showing no evidence to confirm the diagnosis of
hemochromatosis, Wilson disease, alpha-1 antitrypsin de-
ficiency, and autoimmune hepatitis, respectively.
In more detailed history taking, the patient declared
the use of a fungicide called tebuconazole to blend with
barley seeds before planting while, unlike his colleagues,
he was not using masks and gloves. In addition, the patient
stated that pruritus, redness of the eyes, and mild cough
appeared after the completion of the work. Therefore, his
medical history, the physical examination, and laboratory
tests indicated tebuconazole poisoning. The patient was
discharged and advised to avoid any exposure to the fungi-
cide. Two weeks after discharge, we rechecked the patient’s
tests. Interestingly, the results of the new tests showed
complete improvement in the levels of liver enzymes.
3. Discussion
The use of fungicidal agents is very common in agricul-
ture although environmental contamination is a concern.
To prevent the contaminants, it is essential to manage the
use of fungicidal agents. Tebuconazole is a systemic fungi-
cidal agent from the triazole group, which prevents the
biosynthesis of ergosterol in the fungal cell membrane and
stops the growth of fungal pathogens (5). Tebuconazole is
available with two brand names, Roxil and Folicur, to use
in planting seeds, especially wheat and barley, against fun-
gal diseases such as hidden and obvious blackheads (6).
This fungicide is marketed in the form of colorless crystals
that are soluble in most organic solvents. Tebuconazole
has good resistance in soil and seed and is resistant to high
temperature, as well. This compound is harmful to bees,
fish, and other creatures (7).
Triazole Conazole fungicides are metabolized in liver
microsomes (8). Many pesticides and poisons accumulate
in high concentrations in the liver. As a result, the most de-
structive effects of toxins are visible in this organ (9). In
the present study, as reported, two weeks after avoiding the
poison, the liver enzymes returned to their normal state
and the symptoms disappeared. No study has been done so
far to explore the human pathogenesis of this poison, but
several studies have been conducted on its pathogenicity
in other living organisms. In order to assess the toxic ef-
fect of tebuconazole by histological tissue examination of
gills and liver of Labeo rohita, Selvi et al. studied liver and
tissues exposed to a lethal concentration of tebuconazole,
and reported extensive vacuoles and hepatocytes necrosis
and hepatic capillary congestion (10).
In addition, Knebel et al. evaluated the toxic effects of
propiconazole and tebuconazole on the liver. Their results
showed that tebuconazole acted as an antagonist of the
constitutive androstane receptor, whereas propiconazole
acted as an agonist of this receptor (11).
In conclusion, the risk of developing hepatitis when
being exposed to tebuconazole should be considered. Pro-
tective measures and necessary precautions during han-
dling should be taught to farmers, including wearing
gloves and masks and working in ambient air.
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Table 1. Laboratory Parameters on Admission and Two Weeks After Avoiding Tebuconazole in Our Patient
Test On Admission Two Weeks After Avoiding Tebuconazole Normal Ranges
White blood cell (WBC), per mm3 6720 8200 4500 to 10000
Hemoglobin (Hb), g/dL 12.8 14.1 Male: 13.5 to 17.5; female: 12.0 to 15.5
Platelets count, perµL 202000 358000 150000 to 450000
Erythrocyte sedimentation rate (ESR), mm/h 38 21 0 to 22
Aspartate aminotransferase (AST), IU/L 125 13 Males: 6 to 34; females: 8 to 40
Alanine aminotransferase (ALT), IU/L 220 17 7 to 56
Alkaline phosphatase (ALP), IU/L 511 240 44 to 147
Total bilirubin, mg/dL 1.5 1.3 0.31 to 1.94
Serum creatinine, mg/dL 1.1 0.8 0.84 to 1.21
Figure 1. An overview of the tebuconazole metabolic pathway
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